....The Biology and Potential Therapeutic Effects of Cannabidiol..A Biologia e potenciais efeitos terapêuticos do Cannabidiol.. La biología y los efectos terapéuticos potenciales del cannabidiol....

April 25, 2017
....Researches with cannabinoids..Pesquisas com canabinóides.. Investigaciones con cannabinoides....
....Original Language: ..Idioma original:..Idioma original:....
English
....Share It Now:..Compartilhe:..Compartir:....

June 24, 2015

presented by Nora D. Volkow, Director, National Institute on Drug AbuseSenate Caucus on International Narcotics ControlDrug Caucus Hearing on Barriers to Cannabidiol Research (United States Senate Caucus on International Narcotics Control)"Cannabidiol: Barriers to Research and Potential Medical Benefits"

Mr. Chairman, Ms. Chairwoman, and Members of the Senate Drug Caucus, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to participate in this hearing to share what we know about the biology and the potential therapeutic effects of cannabidiol (CBD), one of the main active chemical compounds found in marijuana. In light of the rapidly evolving interest in the potential use of marijuana and its derivative compounds for medical purposes, it is important to take stock of what we know and do not know about the therapeutic potential of CBD.

Background

To date, 23 states and the District of Columbia have passed laws allowing marijuana to be used for a variety of medical conditions. Fifteen additional states have enacted laws intended to allow access to CBD oil and/or high-CBD strains of marijuana. Interest in the potential therapeutic effects of CBD has been growing rapidly, partially in response to media attention surrounding the use of CBD oil in young children with intractable seizure disorders including Dravet syndrome and Lennox-Gastaut syndrome. While there are promising preliminary data, the scientific literature is currently insufficient to either prove or disprove the efficacy and safety of CBD in patients with epilepsy.i and further clinical evaluation is warranted. In addition to epilepsy, the therapeutic potential of CBD is currently being explored for a number of indications including anxiety disorders, substance use disorders, schizophrenia, cancer, pain, inflammatory diseases and others. My testimony will provide an overview of what the science tells us about the therapeutic potential of CBD and of the ongoing research supported by NIH in this area.

CBD Biology and Therapeutic Rationale

CBD is one of more than 80 active cannabinoid chemicals in the marijuana plant.ii Unlike the main psychoactive cannabinoid in marijuana, tetrahydrocannabinol (THC), CBD does not produce euphoria or intoxication.iii,iv,v Cannabinoids have their effect mainly by interacting with specific receptors on cells in the brain and body: the CB1 receptor, found on neurons and glial cells in various parts of the brain, and the CB2 receptor, found mainly in the body’s immune system. The euphoric effects of THC are caused by its activation of CB1 receptors. CBD has a very low affinity for these receptors (100 fold less than THC) and when it binds it produces little to no effect. There is also growing evidence that CBD acts on other brain signaling systems, and that these actions may be important contributors to its therapeutic effects.ii

Preclinical and Clinical Evidence

Rigorous clinical studies are still needed to evaluate the clinical potential of CBD for specific conditions.i However, pre-clinical research (including both cell culture and animal models) has shown CBD to have a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties.

Anti-Seizure Effects

A number of studies over the last two decades or more have reported that CBD has anti-seizure activity, reducing the severity of seizures in animal models.vi,vii In addition, there have been a number of case studies and anecdotal reports suggesting that CBD may be effective in treating children with drug-resistant epilepsy.viii,ix,x However, there have only been a few small randomized clinical trials examining the efficacy of CBD as a treatment for epilepsy; the total number of subjects enrolled in these studies was 48. Three of the four studies reported positive results, including decreased frequency of seizures. However, the studies suffered from significant design flaws, including failure to fully quantify baseline seizure frequency, inadequate statistical analysis, and a lack of sufficient detail to adequately evaluate and interpret the findings.viii Therefore, the currently available information is insufficient to draw firm conclusions regarding the efficacy of CBD as a treatment for epilepsy; a recent Cochrane review concluded, there is a need for “a series of properly designed, high quality, and adequately powered trials.”xi

NIDA is currently collaborating with the National Institute on Neurological Disorders and Stroke to evaluate CBD in animal models of epilepsy in order to understand the underlying mechanisms and optimize the conditions under which CBD may treat seizure disorders, and determine whether it works synergistically with other anti-seizure medications. In addition, clinical trials are currently underway by GW Pharmaceuticals, testing the efficacy of Epidiolex, a purified CBD extract, for treatment of pediatric epilepsy.

Neuroprotective and Anti-Inflammatory Effects

CBD has also been shown to have neuroprotective properties in cell cultures as well as in animal models of several neurodegenerative diseases, including Alzheimer’s,xii,xiii,xiv stroke,xvglutamate toxicity,xvi multiple sclerosis (MS),xvii Parkinson’s disease,xviii and neurodegeneration caused by alcohol abuse.xix Nabiximols (trade name Sativex), which contains THC and CBD in roughly equal proportions, has been approved throughout most of Europe and in a number of other countries for the treatment of spasticity associated with MS. It has not been approved in the United States, but clinical trials are ongoing, and two recent studies reported that nabiximols reduced the severity of spasticity in MS patients.xx,xxi There have been limited clinical trials to assess the potential efficacy of CBD for the other indications highlighted; however, a recent small double-blind trial in patients with Parkinson’s disease found the CBD improved quality-of-life scores.xxii

Analgesic Effects

There have been multiple clinical trials demonstrating the efficacy of nabiximols on central and peripheral neuropathic pain, rheumatoid arthritis, and cancer pain.xxiii In addition, nabiximols is currently approved in Canada for the treatment of central neuropathic pain in MS and cancer pain unresponsive to opioid therapy. However, the current evidence suggests that the analgesia is mediated by THC and it is unclear whether CBD contributes to the therapeutic effects.xxiv THC alone has been shown to reduce pain;xxv,xxvi we are unaware of clinical studies that have explored the efficacy of CBD alone on pain. However, the anti-inflammatory properties of CBD (discussed above) could be predicted to play a role in the analgesic effects of nabiximols. Recent research has also suggested that cannabinoids and opioids have different mechanisms for reducing pain and that their effects may be additive, which suggests that combination therapies may be developed that may have reduced risks compared to current opioid therapies. However, this work is very preliminary.xxvii

Anti-Tumor Effects

In addition to the research on the use of cannabinoids in palliative treatments for cancer—reducing pain and nausea and in increasing appetite—there are also several pre-clinical reports showing anti-tumor effects of CBD in cell culture and in animal models.xxviii These studies have found reduced cell viability, increased cancer cell death, decreased tumor growth, and inhibition of metastasis (reviewed in McAllister et al, 2015).xxix These effects may be due to the antioxidant and anti-inflammatory effects of CBD;xxx however these findings have not yet been explored in human patients. There are multiple industry sponsored clinical trials underway to begin to test the efficacy of CBD in human cancer patients.

Anti-Psychotic Effects

Marijuana can produce acute psychotic episodes at high doses, and several studies have linked marijuana use to increased risk for chronic psychosis in individuals with specific genetic risk factors. Research suggests that these effects are mediated by THC, and it has been suggested that CBD may mitigate these effects.xxxi There have been a few small-scale clinical trials in which patients with psychotic symptoms were treated with CBD, including case reports of patients with schizophrenia that reported conflicting results; a small case study in patients with Parkinson’s disease with psychosis, which reported positive results; and one small randomized clinical trial reporting clinical improvement in patients with schizophrenia treated with CBD.xxxiiLarge randomized clinical trials would be needed to fully evaluate the therapeutic potential of CBD for patients with schizophrenia and other forms of psychosis.

Anti-Anxiety Effects

CBD has shown therapeutic efficacy in a range of animal models of anxiety and stress, reducing both behavioral and physiological (e.g., heart rate) measures of stress and anxiety.xxxiii,xxxiv In addition, CBD has shown efficacy in small human laboratory and clinical trials. CBD reduced anxiety in patients with social anxiety subjected to a stressful public speaking task.xxxv In a laboratory protocol designed to model post-traumatic stress disorders, CBD improved “consolidation of extinction learning”, in other words, forgetting of traumatic memories.xxxvi The anxiety-reducing effects of CBD appear to be mediated by alterations in serotonin receptor 1a signaling, although the precise mechanism remains to be elucidated and more research is needed.xxxvii

Efficacy for Treating Substance Use Disorders

Early preclinical findings also suggest that CBD may have therapeutic value as a treatment of substance use disorders. CBD reduced the rewarding effects of morphinexxxviii and reduced cue-induced heroin seekingxxxix in animal models. A few small clinical trials have examined CBD and/or nabiximols (THC/CBD) for the treatment of substance use disorders; however, the available data are not sufficient to draw conclusions. NIDA is supporting multiple ongoing clinical trials in this area.

Safety of CBD

For reasons discussed previously, despite its molecular similarity to THC, CBD only interacts with cannabinoid receptors weakly at very high doses (100 times that of THC),xl and the alterations in thinking and perception caused by THC are not observed with CBD.iii.iv,v The different pharmacological properties of CBD give it a different safety profile from THC.

A review of 25 studies on the safety and efficacy of CBD did not identify significant side effects across a wide range of dosages, including acute and chronic dose regimens, using various modes of administration.xli CBD is present in nabiximols which, as noted earlier, is approved throughout most of Europe and in other countries. Because of this, there is extensive information available with regard to its metabolism, toxicology, and safety. However, additional safety testing among specific patient populations may be warranted should an application be made to the Food and Drug Administration.

Research Opportunities and Challenges

This is a critical area for new research. While there is preliminary evidence that CBD may have therapeutic value for a number of conditions, we need to be careful to not get ahead of the evidence. Ninety-five percent of drugs that move from promising preclinical findings to clinical research do not make it to market. The recently announced elimination of the PHS review of non-federally funded research protocols involving marijuana is an important first step to enhance conducting research on marijuana and its components such as CBD. Still, it is important to try to understand the reasons for the lack of well-controlled clinical trials of CBD including: the regulatory requirements associated with doing research with Schedule I substances, including a requirement to demonstrate institutional review board approval; and the lack of CBD that has been produced under the guidance of Current Good Manufacturing Processes (cGMP) – required for testing in human clinical trials – available for researchers. Furthermore, the opportunity to gather important information on clinical outcomes through practical (non-randomized) trials for patients using CBD products available in state marijuana dispensaries is complicated by the variable quality and purity of CBD from these sources.

Ongoing CBD Research

The NIH recognizes the need for additional research on the therapeutic effects of CBD and other cannabinoids, and supports ongoing efforts to reduce barriers to research in this area. NIH is currently supporting a number of studies on the therapeutic effects as well as the health risks of cannabinoids. These include studies of the therapeutic value of CBD for:

Treatment of substance use disorders (opioids, alcohol, cannabis, methamphetamine)Attenuation of the cognitive deficits caused by THCNeuropathic pain due to spinal cord injuryMitigating the impact of cannabis use on risk for schizophreniaExamination of the potential of CBD as an antiepileptic treatment

It is important to note that NIDA’s mission is focused on drug abuse; studies related to the therapeutic effects of CBD in other areas would be funded by the Institute or Center responsible for that program area. For example, studies related to epilepsy will likely be funded by the National Institute of Neurological Disorders and Stroke or by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, while studies related to schizophrenia will likely be funded by the National Institute on Mental Health.

Conclusion

There is significant preliminary research supporting the potential therapeutic value of CBD, and while it is not yet sufficient to support drug approval, it highlights the need for rigorous clinical research in this area. There are barriers that should be addressed to facilitate more research in this area. We appreciate the opportunity to testify on the potential use of CBD for therapeutic purposes. Thank you again for inviting me here today, and I look forward to any questions you may have.

References

See original source here

....This information is presented for educational purposes only. 1Pure provides this information to give an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by 1Pure and none should be inferred. ..Esta informação é apresentada apenas para fins educacionais. 1Pure fornece informações para dar uma compreensão das aplicações potenciais do canabidiol. Links para sites de terceiros não constituem um endosso dessas organizações por parte da 1Pure e nada deve ser inferido. ..1Pure proporciona información para dar una comprensión de las aplicaciones potenciales del canabidiol. Los enlaces a sitios de terceros no constituyen un endoso de estas organizaciones por parte de 1Pure y no se debe inferir nada. ....

....1Pure Team..Equipe 1Pure..Equipo 1Pure....
....1Pure was founded by a group of passionate individuals who were frustrated with the many non-standardized products with basic belief that the choice for a natural, non-psychotropic CBD (Cannabidiol) option should be readily available to those in need. ..A 1Pure foi fundada por um grupo de indivíduos frustrados com a falta de produtos de qualidade e não padronizados na indústria da cannabis. A empresa acredita que um produto seguro, de qualidade, natural e não-psicoativo deve ser amplamente disponível para aqueles que necessitam. ..La 1Pure fue fundada por un grupo de individuos frustrados por la falta de productos de calidad y no estándar en la industria del cannabis. La compañía cree que un producto seguro, de calidad, natural y no psicoactivo debe ser ampliamente disponible para los necesitados. ....

....Related Posts..Postagens Relacionadas..Materias Relacionadas....

....DISCLAIMER: Any and all statements made in regard to Cannabinoid products are not expressed as medical claims. Our intention is to educate, not to suggest results nor to encourage action on the part of the reader. 1Pure is not responsible for, and expressly disclaims all liability for, damages of any kind arise out of use, reference to, or reliance on any information contained within the site. The information contained within the site is periodically updated, there is no guarantee to the accuracy of the information. Nothing on this site is intended to operate as legal advice, please seek your own legal advice. FDA DISLAIMER: The statements and products referred to throughout this site have not been evaluated by the FDA. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult a physician or your health care provider. Always consult a medical doctor before modifying your diet, using any new product, drug, supplement, or doing new exercises. We recommend you educate yourselves on the scientific / nutritional facts. .. AVISO DE ISENÇÃO DE RESPONSABILIDADE: Todas e quaisquer declarações feitas em relação aos produtos contendo canabinóides não são expressas como reivindicações médicas. Nossa intenção é educar, não sugerir resultados nem encorajar que o leitor tome qualquer iniciativa. A 1Pure não se responsabiliza e expressamente se abstém de toda a responsabilidade por danos de qualquer tipo que sugirem ou que façam referência a qualquer informação contida no site. As informações contidas no site são atualizadas periodicamente, mas não há garantia de sua precisão. Nada neste site é destinado a funcionar como aconselhamento jurídico. Por favor, procure o seu próprio aconselhamento jurídico. AVISO DE ISENÇÃO DE RESPONSABILIDADE DO AGÊNCIA DE VIGILÂNCIA SANITÁRIA: As declarações e produtos especificados neste site não foram avaliados pela Agência de Vigilância Sanitária (Anvisa) nem pelo Ministério da Agricultura. Eles não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. Se você tem alguma condição de saúde ou sente desconforto, consulte um médico ou outro profissional de saúde. Sempre consulte um médico antes de modificar sua dieta e fazer uso de qualquer produto, droga ou suplemento novo, ou caso mude seus exercícios. Recomendamos que pesquisem mais sobre as informações científicas e nutricionais do produto. ..CLÁUSULA DE EXENCIÓN DE RESPONSABILIDAD: Cualquiera y todas las declaraciones hechas con respecto a los productos de cannabinoides no se expresan como reclamaciones médicas. Nuestra intención es educar, no sugerir resultados o estimular al lector a tomar cualquier iniciativa.  La 1Pure no se hace responsable y expresamente se abstiene de toda responsabilidad por cualquier tipo de daño que emerger o se referir a cualquier información contenida en este sitio. La información contenida en este sitio se actualiza periódicamente, pero no hay ninguna garantía de su exactitud. Nada en este sitio tiene la intención de actuar como un consejo legal. Por favor, busque su propio consejo legal. CLÁUSULA DE EXENCIÓN DE RESPONSABILIDAD DE LA AGENCIA REGULATORIA DE MEXICO Las declaraciones y los productos mencionados en este sitio no han sido evaluados por la Agencia Regulatoria de Mexico. Ellos no se destinan a diagnosticar, tratar, curar o prevenir ninguna enfermedad. Si usted tiene alguna condición de salud o siente molestias, consulte a un médico u otro profesional de la salud. Siempre consulte a un médico antes de cambiar su dieta y hacer uso de cualquier producto, medicamento o suplemento nuevo, o si cambia sus entrenamientos. Recomendamos que haga más investigaciones sobre la información científica y nutricional del producto. ....

Top